Forte Biosciences

Historical price data

Forte Biosciences' mission is to develop and commercialize novel live biotherapeutic products that modulate the skin microbiome to treat inflammatory and autoimmune conditions. Its primary achievement is advancing its lead candidate, FB-401, through Phase 1/2 clinical trials in atopic dermatitis, generating promising early efficacy and safety data. The company's strategy is to focus its resources on progressing FB-401 through later-stage trials, seeking to establish clinical proof-of-concept for its platform and secure strategic partnerships or eventual regulatory approval. As a micro-cap, single-asset biotech, its near-term trajectory is binary and tied directly to FB-401's clinical outcomes.

Proprietary platform for developing topical live biotherapeutic products (LBPs), utilizing selected strains of commensal skin bacteria to restore a healthy microbiome and treat inflammatory skin diseases.

Forte competes in the broad AD market against entrenched steroids, biologics, and JAK inhibitors, and in the niche microbiome space against other early-stage LBP developers. Its differentiation is its topical, live bacterial approach, but it faces potential competition from large pharma entering the field.